Recent news on Galsulfase

BioMarin Submits New Drug Application for US Marketing ...  -  25 May 2007
PR Newswire (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin to Host First Quarter 2007 Financial Results Conference ...  -  Apr 20, 2007
PharmaLive.com (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin Announces Closing of $324875000 Public Offering of Senior ...  -  Apr 24, 2007
PharmaLive.com (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin to Present at the Cowen and Company 27th Annual Health ...  -  27 Mar 2007
Drug Newswire (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin to Present at the Lehman Brothers Tenth Annual Global ...  -  Mar 13, 2007
PharmaLive.com (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin Announces Date and Time Change of Fourth Quarter and Full ...  -  Feb 19, 2007
Drug Newswire (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin Announces Fourth Quarter and Full Year 2006 Financial Results  -  Feb 20, 2007
PR Newswire (press release),Net sales of Naglazyme(R) (galsulfase), an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI), were $16.3 million for the fourth quarter of

BioMarin to Present at the JPMorgan 25th Annual Healthcare Conference  -  Jan 8, 2007
PharmaLive.com (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin Calls Remaining $51.4 Million of Convertible Notes Due 2008  -  Dec 22, 2006
PR Newswire (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin Announces Third Quarter 2006 Financial Results  Nov 1, 2006
Net sales of Naglazyme(R) (galsulfase), an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI), were $12.9 million for the third quarter of 2006 ... -PR Newswire (press release), BioMarin Announces Third Quarter 2006 Financial Results  Nov 1, 2006
...on track to initiate a study of 6R-BH4 in peripheral arterial disease by the end of the year." Product Sales Net sales of Naglazyme(R) (galsulfase), an enzyme ... -PR Newswire (press release), BioMarin to Present at the Cowen and Company 7th Annual Global ...  Nov 2, 2006
Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... -Earthtimes.org BioMarin Completes Enrollment of Phase 2 Clinical Study of 6R-BH4 ...  Sep 21, 2006
Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... -PipelineReview.com

BioMarin to Present at BioCentury's NewsMakers in the Biotech ...  Aug 31, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... -Yahoo! News

BioMarin Announces US Launch of Orapred ODT Through Alliant ...  29 Aug 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... -PR Newswire

BioMarin Announces Second Quarter 2006 Financial Results  Aug 2, 2006
Phase 2 study of 6R-BH4 for the treatment of poorly controlled hypertension in early 2007." Product Sales Net sales of Naglazyme(TM) (galsulfase), an enzyme ... -PR Newswire

Alfimeprase to succeed Genentech's alteplase?  Aug 2, 2006
...products followed, including Aldurazyme (laronidase), from Genzyme and BioMarin Pharmaceutical, in 2003, and, in 2005, Naglazyme (galsulfase) from BioMarin of ... -Nature.com (subscription)

BioMarin Announces Second Quarter 2006 Financial Results  Aug 2, 2006
Net sales of Naglazyme(TM) (galsulfase), an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI), for the second quarter of 2006 were $10.3 million ... -Yahoo! News

BioMarin Initiates Phase 2 Clinical Study Of 6R-BH4 In Poorly ...  Jul 7, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... -Medical News Today



Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 ...  May 11, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... - Genetic Engineering News

BioMarin Announces First Quarter 2006 Financial Results  May 3, 2006
...provide BioMarin the opportunity to address an unmet medical need faced by a significant number of adults." Net sales of Naglazyme(TM) (galsulfase), an enzyme ... - PR Newswire

BioMarin Announces First Quarter 2006 Financial Results  May 3, 2006
Net sales of Naglazyme(TM) (galsulfase), an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI), for the first quarter of 2006 were $7.0 million. ... - PR Newswire





BioMarin Announces Closing of $295 Million Concurrent Public ...  Mar 30, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... - PR Newswire



BioMarin to Present at Cowen & Co. 26th Annual Health Care ...  Feb 27, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - Yahoo! News

BioMarin Announces Fourth Quarter and Year-End 2005 Financial ...  Feb 23, 2006
Net sales of Naglazyme(TM) (galsulfase), an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI), for the fourth quarter and year ended December 31 ... - PR Newswire,

BioMarin Receives Marketing Approval for Naglazyme in European ...  Jan 30, 2006
...(Nasdaq and SWX: BMRN) announced today that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific ... - MSN Money

BioMarin Receives Marketing Approval for Naglazyme in European ...  Jan 30, 2006
...announced today that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific treatment approved in the ... - PharmaLive.com

BioMarin Establishes Commercial Operations in Europe  Jan 10, 2006
...that it has established commercial operations in Europe in anticipation of receiving European marketing approval for Naglazyme(TM) (galsulfase), an enzyme ... - PR Newswire

BioMarin Receives FDA Fast Track Designation for Phenoptin for PKU  Jan 25, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - PR Newswire

BioMarin Receives Marketing Approval for Naglazyme in European ...  Jan 31, 2006
...announced yesterday that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific treatment approved in ... - DG News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional